Combination treatment of photodynamic therapy with verteporfin and intravitreal ranibizumab in patients with retinal angiomatous proliferation

Autor:	Anton Haas, Martin Weger, Christoph Werner, Gerald Seidel, Iris Steinbrugger
Rok vydání:	2013
Předmět:	Indocyanine Green Male Vascular Endothelial Growth Factor A medicine.medical_specialty Visual acuity Porphyrins genetic structures Population Visual Acuity Angiogenesis Inhibitors Retinal Neovascularization Antibodies Monoclonal Humanized Loading dose Macular Degeneration Endophthalmitis Ophthalmology Ranibizumab medicine Humans Prospective Studies Fluorescein Angiography education Coloring Agents Aged education.field_of_study Photosensitizing Agents medicine.diagnostic_test business.industry Verteporfin General Medicine Macular degeneration Fluorescein angiography medicine.disease Combined Modality Therapy Surgery Photochemotherapy Intravitreal Injections Female medicine.symptom business Tomography Optical Coherence medicine.drug
Zdroj:	Acta ophthalmologica. 91(6)
ISSN:	1755-3768
Popis:	Purpose: To investigate the efficacy and safety of initial photodynamic therapy (PDT) with a ranibizumab loading dose of three monthly intravitreal injections and a subsequent PRN ranibizumab regimen in the treatment of retinal angiomatous proliferation (RAP). Methods: In this 12-month prospective case series, 15 patients underwent PDT followed by 3 intravitreal ranibizumab injections at monthly intervals. At monthly follow-up examinations, further single ranibizumab injections were given in case of any intra- or subretinal fluid on optical coherence tomography (OCT), visual loss ≥5 letters or signs of activity on fluorescein or indocyanine green angiography. Results: Best-corrected visual acuity (BCVA) improved from 58.1 ± 13.2 at baseline by 9.2 letters (SD ± 8.5; p = 0.004) at 6 months and by 8.7 letters (SD ± 11.4; p = 0.017) at 12 months. Neither at 6 nor at 12 months, any patient had lost ≥15 letters. The mean number of injections per patient was 4.8 (SD ± 1.4) in the first year of therapy after PDT. The average time to first retreatment was 3.7 months (range 1–7 months). No serious adverse events, such as endophthalmitis or retinal detachment, were noted. Conclusion: PDT with 3 ranibizumab loading injections and subsequent ranibizumab as needed resulted in a significant gain of 8.7 ± 11.4 letters at month 12. This regimen is safe and efficacious, but even in a population of mostly early stages of RAP, retreatment rates remained high.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e4a55276784c5258e0059c32ff0f9e9 https://pubmed.ncbi.nlm.nih.gov/23786546 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.